EQS-News: BB BIOTECH AG
/ Key word(s): Dividend
Release as at February 14, 2024 After a difficult 2023 stock market year, above all due to higher interest rates, the capital markets are now once again looking at biotech companies with interest. The prospect of falling interest rates has led to a rethink. While the majority of investors favor large biotech companies, the giants of this industry are competing for the acquisition of smaller biotech players in order to further expand their pipeline and access to technology. The latest rise in acquisition activity, combined with a stronger capital market that makes it easier for companies to procure operating capital again, is not only supporting the sector – it also shows that biotechs are very attractively valued and that impressive innovative strength remains an enduring feature of smaller and mid-cap biotech companies. As a result of this recovery trend, the net asset value of BB Biotech showed a positive performance of 1.8% in terms of USD in 2023, although currency depreciation meant that the performance was negative in CHF (-7.4%) and EUR (-1.3%). The stock was unable to keep up with this development: its overall performance came in at -18.1% in CHF and -15.2% in EUR. As a consequence, the premium shrank over the course of the year to the point where the stock was trading at around book value at the year-end. Dividend remains high Numerous stimuli for 2024 A number of important milestones have already been reached by the BB Biotech portfolio in the first few weeks of the year. In January, leading company Vertex announced positive results from its Phase III studies involving VX-548 to treat acute post-operative and non-operative pain. An oral, selective NaV1.8 inhibitor, VX-548 has demonstrated a significant reduction in pain without the dependency risk of opioids, which is an important aspect given the backdrop of the opioid crisis in the US. The company is planning to submit an application for authorization to the FDA by mid-2024. This program should prove to be one of the next major commercial successes of Vertex following the very impressive success of the company’s cystic fibrosis drug. Meanwhile, Alnylam’s HELIOS-B program to treat patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM) should likewise prove very important in the fourth quarter of the year – and not just for Alnylam itself, but also for Ionis, BB Biotech's largest investment. Another key milestone is the publication of the results of Intra-Cellular Therapies Phase III study on the treatment of severe depression. In addition, numerous potential product authorizations are on the cards, Moderna being a good example. This company is expecting to receive authorization for its vaccine against respiratory-syncytial virus (RSV). These promising fundamental stimuli, coupled with a constructive capital market environment, a pick-up in M&A activities and historically low valuations should offer investors an attractive entry point. BB Biotech key data
* Calculated on the volume-weighted average price of the stock in December of the fiscal year in question, the dividend being proposed by the Board of Directors of BB Biotech equates to a dividend yield of 5%.
Investor Relations Media Relations TE Communications AG, Bleichestrasse 11, 9000 St. Gallen, Schweiz, Tel. +41 79 423 22 28 www.bbbiotech.com Company profile Disclaimer
14.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | BB BIOTECH AG |
Schwertstrasse 6 | |
8200 Schaffhausen | |
Switzerland | |
Phone: | +41 52 624 08 45 |
E-mail: | info@bbbiotech.com |
Internet: | www.bbbiotech.ch |
ISIN: | CH0038389992 |
WKN: | A0NFN3 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Mailand, SIX |
EQS News ID: | 1836461 |
End of News | EQS News Service |
|
1836461 14.02.2024 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.